CN112402409A - Application of hesperetin in preparation of drugs for inhibiting beta-secretase activity - Google Patents
Application of hesperetin in preparation of drugs for inhibiting beta-secretase activity Download PDFInfo
- Publication number
- CN112402409A CN112402409A CN202011436644.7A CN202011436644A CN112402409A CN 112402409 A CN112402409 A CN 112402409A CN 202011436644 A CN202011436644 A CN 202011436644A CN 112402409 A CN112402409 A CN 112402409A
- Authority
- CN
- China
- Prior art keywords
- hesperetin
- secretase
- activity
- beta
- peretin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title claims abstract description 49
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title claims abstract description 49
- 230000000694 effects Effects 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 11
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 title claims description 49
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 title claims description 49
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 title claims description 49
- 229960001587 hesperetin Drugs 0.000 title claims description 49
- 235000010209 hesperetin Nutrition 0.000 title claims description 49
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 title claims description 49
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 11
- 235000013361 beverage Nutrition 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 abstract description 10
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract description 8
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract description 8
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract description 8
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract description 8
- 230000013016 learning Effects 0.000 abstract description 8
- 238000009825 accumulation Methods 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- 238000003776 cleavage reaction Methods 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000007017 scission Effects 0.000 abstract description 3
- 239000002439 beta secretase inhibitor Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 10
- 238000003032 molecular docking Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 7
- 102000054727 Serum Amyloid A Human genes 0.000 description 7
- 108700028909 Serum Amyloid A Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 6
- 238000012347 Morris Water Maze Methods 0.000 description 6
- XJBUEKXIUDQBPI-UHFFFAOYSA-N 6-chloro-n-(6-phenylmethoxy-1h-benzimidazol-2-yl)imidazo[1,2-a]pyridine-2-carboxamide Chemical compound C=1N2C=C(Cl)C=CC2=NC=1C(=O)NC(NC1=CC=2)=NC1=CC=2OCC1=CC=CC=C1 XJBUEKXIUDQBPI-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000004386 Erythritol Substances 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 229960004977 anhydrous lactose Drugs 0.000 description 4
- 235000019414 erythritol Nutrition 0.000 description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 4
- 229940009714 erythritol Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- 229940125759 BACE1 protease inhibitor Drugs 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 102100021257 Beta-secretase 1 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229940106134 krill oil Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- DVMUZHLUMHPCGZ-QGZVFWFLSA-N n-[3-[(4r)-2-amino-5,5-difluoro-4-methyl-6h-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C(F)C=1[C@@]1(C)N=C(N)OCC1(F)F DVMUZHLUMHPCGZ-QGZVFWFLSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical group C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了橘皮素在制备抑制β分泌酶活性药物中的应用，同时本发明还公开了橘皮素在制备用于治疗由β分泌酶活性增强所致的疾病的药物中的应用。本发明首次发掘了橘皮素的作用靶点为β分泌酶，本发明发现并验证了橘皮素具有与β分泌酶抑制剂相似的结合β分泌酶的能力，橘皮素通过与β分泌酶结合并抑制其活性，减少了β分泌酶对淀粉样蛋白前体蛋白的错误剪切，进而降低了脑内淀粉样蛋白Aβ的产生和错误堆积，从而达到改善阿尔兹海默症，增强学习记忆能力的作用。并且由于橘皮素具有抑制β分泌酶活性的作用，因此任何由于β分泌酶活性增强导致的疾病均可通过橘皮素进行改善和治疗。
The invention discloses the application of orange peretin in preparing a drug for inhibiting beta-secretase activity, and also discloses the application of orange peretin in preparing a drug for treating diseases caused by enhanced beta-secretase activity. The present invention discovers for the first time that the action target of orange peretin is β-secretase. The present invention finds and verifies that orange peretin has the ability to bind to β-secretase similar to that of β-secretase inhibitors. Combined with and inhibit its activity, it reduces the incorrect cleavage of amyloid precursor protein by beta secretase, thereby reducing the production and incorrect accumulation of amyloid Aβ in the brain, thereby improving Alzheimer's disease and enhancing learning and memory. role of ability. And because orange peretin has the effect of inhibiting the activity of β-secretase, any disease caused by the enhanced activity of β-secretase can be improved and treated by orange peretin.
Description
Technical Field
The invention relates to the technical field of medical health products, in particular to application of hesperetin in preparation of a drug for inhibiting beta secretase activity.
Background
Alzheimer's Disease (AD), also known as senile dementia, is a highly harmful senile disease. According to statistics, the incidence of the disease is increasing year by year in China. With the aging of our society, alzheimer's disease will bring huge medical and financial expenses and social burden. Therefore, the development of drugs capable of alleviating or treating the disease has been a hot point of research.
The current mainstream theory holds that one of the main causes of alzheimer's disease is the wrong accumulation of amyloid a β in the brain, resulting in neurotoxic senile plaques, eventually leading to neuronal death. In the brain, Amyloid Precursor Protein (APP) is mis-cleaved by beta-secretase (BACE-1) and gamma-secretase to produce Amyloid A β, where BACE-1 cleavage of APP is the rate-limiting step in this pathway. Therefore, to interfere with amyloid A β production, one major research focus has been on limiting the activity of BACE-1. However, several drugs known so far, such as BACE-1 inhibitors, virally-entrapped BACE1-siRNA, etc., generally have unthinkable side effects, such as severe retinopathy or other safety issues. At present, no proper safe specific medicine is available at home and abroad.
A series of secondary metabolite plant compounds (phytochemicals) derived from plants have been proved to have good pharmacological functions in recent years, and particularly, flavonoid substances derived from edible fruits and vegetables have the characteristics of good drug effect and low toxic and side effects, so that the phytochemicals are widely concerned and developed into commodities such as medicines, dietary supplements and the like. Among them, the polymethoxyflavonoids of hesperetin found in citrus fruits have been confirmed to have excellent pharmacological actions such as oxidation resistance, inflammation resistance, liver protection, nerve protection, etc., and the prior art also discloses that hesperetin has an action of preventing dementia of the alzheimer type. However, no research on the action target of the hesperetin on the Alzheimer disease exists at present.
Disclosure of Invention
The invention aims to provide application of hesperetin in preparation of a drug for inhibiting activity of beta-secretase, and the invention discovers that the beta-secretase (BACE-1) is a molecular target of the hesperetin for the first time, namely the invention discovers and verifies that the hesperetin can be combined with the BACE-1 and inhibit the activity of the BACE-1, so that the generation of a mistaken shearing product amyloid A beta of the hesperetin is reduced, the mistaken accumulation of the amyloid A beta in brain is reduced, and the effects of improving Alzheimer's disease and enhancing learning and memory ability are achieved.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention provides application of hesperetin in preparation of a drug for inhibiting beta secretase activity.
The invention also provides the application of the hesperetin in preparing a medicament for treating diseases caused by the enhancement of the activity of beta-secretase.
Further, the disease is alzheimer's disease.
Further, the dosage form of the medicine is any pharmaceutically acceptable dosage form.
Furthermore, the dosage form is tablets, granules, capsules, oral liquid or pills.
Further, the tablet comprises the following components in parts by weight: 55 parts of hesperetin, 44 parts of anhydrous lactose and 1 part of magnesium stearate.
Further, the granules comprise the following components in parts by weight: 75 parts of hesperetin and 25 parts of anhydrous lactose.
Further, the hesperetin is prepared into milk powder, beverage or solid beverage.
Further, when the hesperetin is prepared into milk powder, the milk powder comprises the following components in parts by weight: 20 parts of hesperetin, 70 parts of skim milk powder, 5 parts of xylitol and 5 parts of erythritol.
Further, when the hesperetin is prepared into a solid beverage, the solid beverage comprises the following components in parts by weight: 30 parts of hesperetin, 30 parts of skim milk powder, 10 parts of antarctic krill oil powder, 10 parts of inulin, 10 parts of microcrystalline cellulose, 5 parts of xylitol and 5 parts of erythritol.
Compared with the prior art, the invention has the beneficial effects that: the invention discovers and verifies that the hesperetin has the ability of combining beta secretase similar to that of a beta secretase inhibitor, and the hesperetin is combined with the beta secretase and inhibits the activity of the beta secretase, so that the error shearing of the beta secretase on amyloid precursor protein is reduced, the generation and error accumulation of amyloid A beta in brain are further reduced, and the effects of improving Alzheimer's disease and enhancing learning and memory capacity are achieved. And any disease caused by the enhancement of beta-secretase activity can be improved and treated by the hesperetin because the hesperetin has the effect of inhibiting the beta-secretase activity.
Drawings
FIG. 1 is a graph showing the results of molecular docking simulation of hesperetin and BACE1-IN-1 with the known inhibitor of beta-secretase activity BACE1 IN example 1 of the present invention, wherein A is the best docking result of hesperetin and BACE-1, and B is the best docking result of BACE-IN-1 and BACE-1;
FIG. 2 is a graph showing the detection results of the escape latency of mice in Morris water maze training for 5 days in example 2 of the present invention;
FIG. 3 is a result of measuring the number of times that a mouse passes through a platform region in a space exploration experiment, when the Morris water maze is trained for 6 days in example 2 of the present invention;
FIG. 4 is a graph showing the results of detecting the expression level of s-APP β protein in mouse brain tissue in example 2 of the present invention, wherein A is the result of immunoblot detection and B is the result of quantitative detection of the expression level of s-APP β protein.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments of the present invention, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
EXAMPLE 1 inhibition of BACE-1 Activity by hesperetin
This example compares the binding ability of an hesperetin molecule (available from Douguerie scientific development Co., Ltd.) and a known chemically synthesized BACE-1 inhibitor BACE1-IN-1 (available from Shanghai ceramic Biotechnology Co., Ltd.) to BACE1 by molecular docking simulation, and is specifically performed as follows:
BACE-1 molecules (PDB ID: 2WJO) had small molecules (QUD) and all water molecules bound to them removed by PyMOL Molecular Graphics System (2.4.0) software, and had the charge equally distributed and hydrogen atoms added by Autodock tools 4.2. Structural documents of both hesperetin and BACE-IN-1 molecules were downloaded IN the NCBI database. The software used for molecular docking is autodock4.2, the docking algorithm is a ramak genetic algorithm, and the range of molecular docking is the overall structure of BACE-1.
Docking results are shown IN FIG. 1, A is the best docking mode of hesperetin and BACE-1, and B is the best docking mode of BACE-IN-1 and BACE-1. According to the results, both the hesperetin and the BACE-IN-1 can be docked with the BACE-1, namely the hesperetin has the similar ability of binding BACE-1 molecules with a BACE-1 inhibitor and has approximate binding energy, wherein the binding energy of the hesperetin and the BACE-1 is-5.82 kcal/mol, and the binding energy of the BACE-IN-1 and the BACE-1 is-6.24 kcal/mol. The molecular structure of the hesperetin is proved to have the potential of inhibiting BACE-1.
Example 2 improvement of learning and memory ability and inhibition of BACE-1 Activity of hesperetin in APP/PS1 mice: an Alzheimer's disease transgenic mouse model, namely an APP/PS1 double transgenic mouse.
The experimental method comprises the following steps: 12 February half-aged APP/PS1 mice were selected and divided into two groups on average, the administration group (Tangeretin group) was orally intragastrically administered with 100mg/kg hesperetin (dissolved in 1% sodium carboxymethylcellulose aqueous solution) per day, and the model group (APP/PS1 group) was orally intragastrically administered with 1% sodium carboxymethylcellulose aqueous solution of the same volume per day. Four months later, two groups of animals were evaluated for learning and memory levels using the Morris water maze experiment: wherein, when the Morris water maze is trained for 5 days, the detection result of the escape latency of the mouse is shown in figure 2; the results of the detection of the number of times the mouse crossed the platform region in the space exploration experiment when the Morris water maze was trained for 6 days are shown in FIG. 3. The animals were then sacrificed and brain homogenates were taken to measure the expression level of s-APP β protein in the brain tissues of mice in the administration group and model group, and the results are shown in FIG. 4.
The APP/PS1 transgenic mouse selected in the experiment is a double-transgenic animal and can express mutant human presenilin (DeltaE9) and human Amyloid Precursor Protein (APP). The study reports that at six months of age, APP/PS1 mice have A beta deposition in the brain, and have a reduced level of learning and memory caused by A beta deposition. The Morris water maze is a classical behavioral experiment used to evaluate the level of learning and memory in animals.
According to the test results of fig. 2, on the 5 th day of training, mice of the administration group (tageretin) had escape latency significantly shorter than those of the model group (APP/PS1) (p < 0.05); from the results of the examination shown in FIG. 3, in the space exploration experiment performed on the 6 th day of training, the mice of the administration group (Tageretin) found the platform region more easily than the mice of the model group (APP/PS 1). The results in fig. 2 and fig. 3 demonstrate that APP/PS1 mice have significantly improved learning and memory abilities when administered orally with hesperetin.
The immunoblot and s-APP β protein expression quantitative determination results shown in FIG. 4 show that the expression level of s-APP β protein in the brain homogenate of the mice in the administration group (APP/PS1+ Tan) is very significantly reduced (p <0.01) compared with the brain homogenate of the model group (APP/PS1), wherein the s-APP β protein is the protein residue after BACE-1 cleaves APP, which indicates that the activity of BACE-1 is significantly inhibited after the mice take hesperetin orally, thereby reducing the generation of BACE-1 mistaken cleavage product amyloid A β and reducing the mistaken accumulation of amyloid A β in brain, and further treating and improving Alzheimer's disease.
Example 3
The hesperetin can be prepared into different dosage forms or products to prepare medicaments for inhibiting the activity of beta-secretase or medicaments for treating diseases caused by the enhancement of the activity of the beta-secretase.
The hesperetin can be prepared into tablets, which comprise the following components in parts by weight: 55 parts of hesperetin, 44 parts of anhydrous lactose and 1 part of magnesium stearate;
the hesperetin can be prepared into granules, which comprise the following components in parts by weight: 75 parts of hesperetin and 25 parts of anhydrous lactose.
The hesperetin can be prepared into milk powder, which comprises the following components in parts by weight: 20 parts of hesperetin, 70 parts of skim milk powder, 5 parts of xylitol and 5 parts of erythritol.
The hesperetin can be prepared into solid beverage, which comprises the following components in parts by weight: 30 parts of hesperetin, 30 parts of skim milk powder, 10 parts of antarctic krill oil powder, 10 parts of inulin, 10 parts of microcrystalline cellulose, 5 parts of xylitol and 5 parts of erythritol.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention.
Claims (6)
1. Application of hesperetin in preparation of drugs for inhibiting beta-secretase activity.
2. Use of hesperetin for the preparation of a medicament for the treatment of a disease resulting from an enhanced beta-secretase activity.
3. The use according to claim 2, wherein the disease is alzheimer's disease.
4. The use according to claim 1 or 2, wherein the medicament is in any pharmaceutically acceptable form.
5. The use according to claim 4, wherein the dosage form is a tablet, granule, capsule, oral liquid or pill.
6. Use according to claim 1 or 2, wherein the hesperetin is prepared as a milk powder, a beverage or a solid beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011436644.7A CN112402409A (en) | 2020-12-11 | 2020-12-11 | Application of hesperetin in preparation of drugs for inhibiting beta-secretase activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011436644.7A CN112402409A (en) | 2020-12-11 | 2020-12-11 | Application of hesperetin in preparation of drugs for inhibiting beta-secretase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112402409A true CN112402409A (en) | 2021-02-26 |
Family
ID=74775031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011436644.7A Pending CN112402409A (en) | 2020-12-11 | 2020-12-11 | Application of hesperetin in preparation of drugs for inhibiting beta-secretase activity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112402409A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020040052A1 (en) * | 2000-08-17 | 2002-04-04 | Hisatomi Ito | Method for neurite outgrowth |
| CN102458395A (en) * | 2009-06-03 | 2012-05-16 | 富士产业株式会社 | Neurite elongation agent, memory improving agent and anti-alzheimer agent containing 4 '-demethylnobiletin or 4' -demethylhesperetin as active ingredient, and process for producing the same |
| CN102883716A (en) * | 2010-02-26 | 2013-01-16 | 小太郎汉方制药株式会社 | Dried plant tissues and plant tissue extracts for improving central nervous degenerative diseases accompanied by learning/memory disorders and movement disorders, and medicines and foods containing them |
| CN103930106A (en) * | 2012-06-21 | 2014-07-16 | 小太郎汉方制药株式会社 | Composition for improving and/or treating central nervous system degenerative disease |
| US20190314375A1 (en) * | 2018-04-13 | 2019-10-17 | Seung Hyun Yoo | Identification of granins as the pathogenic factor of alzheimer's disease and compositions and methods for inhibiting granin aggregation and treating alzheimer's disease |
| CN110496163A (en) * | 2019-09-26 | 2019-11-26 | 江西中医药大学 | Preparation method of flower buds or flowers or branches or leaves or fruit effective parts or components of citrus plants and their application in the preparation of medicines |
-
2020
- 2020-12-11 CN CN202011436644.7A patent/CN112402409A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020040052A1 (en) * | 2000-08-17 | 2002-04-04 | Hisatomi Ito | Method for neurite outgrowth |
| CN102458395A (en) * | 2009-06-03 | 2012-05-16 | 富士产业株式会社 | Neurite elongation agent, memory improving agent and anti-alzheimer agent containing 4 '-demethylnobiletin or 4' -demethylhesperetin as active ingredient, and process for producing the same |
| CN102883716A (en) * | 2010-02-26 | 2013-01-16 | 小太郎汉方制药株式会社 | Dried plant tissues and plant tissue extracts for improving central nervous degenerative diseases accompanied by learning/memory disorders and movement disorders, and medicines and foods containing them |
| CN103930106A (en) * | 2012-06-21 | 2014-07-16 | 小太郎汉方制药株式会社 | Composition for improving and/or treating central nervous system degenerative disease |
| US20190314375A1 (en) * | 2018-04-13 | 2019-10-17 | Seung Hyun Yoo | Identification of granins as the pathogenic factor of alzheimer's disease and compositions and methods for inhibiting granin aggregation and treating alzheimer's disease |
| CN111971042A (en) * | 2018-04-13 | 2020-11-20 | 刘承铉 | Granule protein for identifying causative agent of Alzheimer's disease, composition and method for inhibiting aggregation of granule protein and treating Alzheimer's disease |
| CN110496163A (en) * | 2019-09-26 | 2019-11-26 | 江西中医药大学 | Preparation method of flower buds or flowers or branches or leaves or fruit effective parts or components of citrus plants and their application in the preparation of medicines |
Non-Patent Citations (5)
| Title |
|---|
| BRAIDY N等: "Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer"s and Parkinson"s Disease", 《CNS NEUROL DISORD DRUG TARGETS》 * |
| YOUN K等: "Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels", 《NUTRIENTS》 * |
| 刘新峰等: "《实验神经病学》", 31 August 2006, 北京：人民军医出版社 * |
| 欧阳新平等: "橘皮素对PC-12细胞Aβ水平的影响及机制研究", 《中南医学科学杂志》 * |
| 熊娅等: "橘红素药理作用研究进展", 《中成药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3215148B1 (en) | Use of low dose of tetrahydrocannabinol for the treatment of cognitive decline in elderly patients | |
| US8148354B2 (en) | Use of 20(S)-protopanaxadiol in manufacture of antidepressants | |
| AU2013348836B2 (en) | Learning and memory improver | |
| CN108236608A (en) | Pharmaceutical composition of cannabidiol and vigabatrin and use thereof | |
| Erdag | Investigation of some phenolic compounds as iNOS inhibitors: An in silico approach | |
| Everett et al. | The pharmacology of medieval sedatives: The “Great Rest” of the Antidotarium nicolai | |
| Zhou et al. | Systems pharmacology uncovers the mechanisms of anti-asthma herbal medicine intervention (ASHMI) for the prevention of asthma | |
| CN106389740A (en) | A composition for preventing and/or delaying age-related cognitive impairment and its application method | |
| JP2013032308A (en) | Pharmaceutical composition for treating/preventing depression | |
| CN112402409A (en) | Application of hesperetin in preparation of drugs for inhibiting beta-secretase activity | |
| Lv et al. | Discovery and characterization of moracin C as an anti-gouty arthritis/hyperuricemia candidate by docking-based virtual screening and pharmacological evaluation | |
| CN105919991A (en) | Application of euparin to preparation of medicine for treating depression | |
| CN108078984B (en) | Composition of serotonin and norepinephrine reuptake inhibitor and cannabidiol and application thereof | |
| CN114129572B (en) | Pharmaceutical composition for synergistically inhibiting tetrandrine-induced drug-induced liver injury | |
| ES2899101T3 (en) | Botanical compositions of Salvia officinalis with activity to extend the chronological life and its uses | |
| JP7490064B2 (en) | Composition for treating fragile X syndrome or related developmental disorders containing Lislead compound as an active ingredient | |
| CN115607588B (en) | Anti-gout apiary extract and non-bestatin pharmaceutical composition for treating both symptoms and root causes and application thereof | |
| CN112972458B (en) | Application of composition in preparation of medicine for treating Alzheimer's disease | |
| Schell | Sceletium tortuosum and mesembrine: a potential alternative treatment for depression | |
| AU2018101586A4 (en) | Uses of polydatin | |
| CN102775455A (en) | Dihydromyricetin medicine treating acute and chronic bronchitis and its preparation method | |
| WO2022007982A2 (en) | Pharmaceutical composition and application thereof | |
| CN113018294A (en) | Application of diosmetin | |
| WO2022204782A1 (en) | Cannabinoid formulation for management of depression, anxiety and ptsd, and cannabinoid formulation as a sleep aid | |
| CN106562985A (en) | Medicinal health care applications of linarin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210226 |